Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 371 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Immune checkpoint inhibitor Clear all

Conditions: Non Small Cell Lung Cancer
Interventions: Apricity C.A.R.E. Program for Cancer Adverse events Rapid Evaluation; Other
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 4
States / cities: New York, New York

Conditions: Squamous Cell Carcinoma of the Head and Neck, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions: Interleukin-15 Superagonist (N-803), CIML NK cell Infusion, Ipilimumab, Cetuximab; Drug · Biological
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Non Small Cell Lung Cancer Metastatic
Interventions: Acasunlimab, Pembrolizumab; Biological
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 6
States / cities: Santa Rosa, California • Fort Myers, Florida • St. Petersburg, Florida + 3 more

Conditions: Stage III Melanoma, Stage IV Melanoma
Interventions: TBX-3400; Biological
Lead sponsor: Taiga Biotechnologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 2
States / cities: Los Angeles, California • Denver, Colorado

Conditions: Non Small Cell Lung Carcinoma, c-MET
Interventions: Telisotuzumab Adizutecan, Budigalimab, Pembrolizumab, Carboplatin, Pemetrexed, Cisplatin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 27
States / cities: Phoenix, Arizona • Fullerton, California • Oxnard, California + 24 more

Conditions: Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Cancer, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer
Interventions: Anti-OX40 Antibody PF-04518600, Axitinib, Laboratory Biomarker Analysis, Placebo; Biological · Drug · Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 9
States / cities: Los Angeles, California • Newport Beach, California • Sacramento, California + 5 more

Conditions: Unresectable Cutaneous Melanoma
Interventions: Axelopran, Nivolumab; Drug
Lead sponsor: John Kirkwood; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Malignant Skin Neoplasm, Melanoma
Interventions: Non-Interventional Study; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Brain Cancer, Brain Neoplasm, Glioma, Glioblastoma, Gliosarcoma, Malignant Brain Tumor, Neoplasm, Neuroepithelial, Neuroectodermal Tumors, Neoplasm by Histologic Type, Neoplasm, Nerve Tissue, Nervous System Diseases
Interventions: DNX-2401, pembrolizumab; Biological
Lead sponsor: DNAtrix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 14
States / cities: Little Rock, Arkansas • Los Angeles, California • Chicago, Illinois + 10 more

Conditions: Urinary Bladder Cancer, Bladder Tumors, Transitional Cell Carcinoma of the Bladder, Malignant Melanoma, Melanoma, Skin Cancer, Carcinoma, Non-Small-Cell Lung, Lung Cancer
Interventions: NEO-PV-01, Nivolumab, Adjuvant; Biological · Other
Lead sponsor: BioNTech US Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 9
States / cities: Duarte, California • Los Angeles, California • San Francisco, California + 4 more

Conditions: Nonsmall Cell Lung Cancer, NSCLC
Interventions: NovoTTF-200T, Immune checkpoint inhibitors or docetaxel; Device · Drug
Lead sponsor: NovoCure GmbH; Industry
Eligibility: 22 Years and older
Enrollment: 291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 73
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 59 more

Conditions: Non Small Cell Lung Cancer Metastatic
Interventions: Radiation, Immuno-Therapeutic Agent; Radiation · Drug
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Neoplasms, Colorectal, Solid Tumor, Colon Cancer, Rectal Cancer, Endometrial Cancer
Interventions: GSK4418959, PD-1 inhibitor; Drug · Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 6
States / cities: Los Angeles, California • Denver, Colorado • Detroit, Michigan + 2 more

Conditions: Solid Tumor, Adult, Solid Tumor, Melanoma, Basal Cell Cancer, Squamous Cell Cancer, Adenoma
Interventions: R-5780; Drug
Lead sponsor: Rise Therapeutics LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Denver, Colorado • Nashville, Tennessee

Conditions: Brain Metastasis, Stereotactic Radiosurgery, Resection, Systemic Therapy
Interventions: Systemic therapy; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Squamous Cell Cancers of the Head and Neck
Interventions: cetuximab, afatinib; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions: Laboratory Biomarker Analysis, Pembrolizumab, Propranolol Hydrochloride; Other · Biological · Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 4
States / cities: Atlanta, Georgia • Buffalo, New York • Cleveland, Ohio + 1 more

Conditions: Non-small Cell Lung Cancer
Interventions: Tiragolumab, Atezolizumab, Pemetrexed, Carboplatin; Drug
Lead sponsor: Liza Villaruz, MD; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Melanoma
Interventions: TAK-580, TAK-202, vedolizumab, nivolumab, ipilimumab; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 14
States / cities: Tucson, Arizona • Los Angeles, California • San Francisco, California + 10 more

Conditions: Advanced Solid Tumors Cancer
Interventions: ABBV-CLS-579, PD-1 inhibitor, VEGFR TKI; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 5
States / cities: Springdale, Arkansas • New Haven, Connecticut • Fort Wayne, Indiana + 2 more

Conditions: Locally Advanced Melanoma
Interventions: Fianlimab + Cemiplimab, Relatlimab + Nivolumab; Drug
Lead sponsor: John Kirkwood; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Cancer, Solid Tumor, Colorectal Cancer, Pancreas Cancer, Non Small Cell Lung Cancer, Head and Neck Cancer, Gynecologic Cancer, Skin Cancer, Kidney Cancer
Interventions: DK210 (EGFR), Radiation therapy, Immune checkpoint blockers, Chemotherapy; Biological · Radiation · Drug
Lead sponsor: DEKA Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 7
States / cities: Duarte, California • Manhasset, New York • Oklahoma City, Oklahoma + 3 more

Conditions: Melanoma, Unresectable Melanoma
Interventions: Sarilumab, Ipilimumab Injection, Nivolumab/Relatlimab; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 100 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Los Angeles, California • Boston, Massachusetts • New York, New York

Conditions: Microsatellite Stable (MSS) Colorectal Cancer (CRC), Metastatic Colorectal Cancer (CRC), Colorectal Cancer Stage IV
Interventions: Pre-Treatment Biopsy, On-Treatment Biopsy, Tiragolumab, Atezolizumab, Bevacizumab; Procedure · Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Search by objective public record fields.

Apricity CARE to Improve ICI Outcomes of Ethnic/Racial Minority NSCLC Patients

CIML NK Cell in Head & Neck Cancer

Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer

Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer

Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma

Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity Using the Vigilant App

Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects

A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer

Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)

Hypofractionated Radiation Therapy to Improve Immunotherapy Response in Non-Small Cell Lung Cancer

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors

OBSERVE: A Pilot Study Of Omission Of Brain Metastasis Stereotactic Radiosurgery Following Resection With CNS-Active Systemic Therapy

Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck

Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery

Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases

Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma

First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors

Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer